RE:RE:RE:Discussions Involve Multiple Partners in Varying FormatsQT, yes, I agree with your last comment.
"Jardiance (co-owned by Boehringer Ingelheim and Eli Lilly) and Januvia (Merck & Co.) are the current SGLT2i and DPP4i market leaders, respectively. The market penetration of these treatments is expected to grow significantly over the next five years, with the potential global market value of approximately US$25 billion by 2024 (Mordor Intelligence 2019). However, no diabetes medication alone (including SGLT2i and DPP4i) has been shown to reduce MACE in patients with recent ACS and substantial residual risk remains for this population. " (Bolding and underscoring added to make the point)
It would be a missed opportunity for Jardiance and others not to take advantage of Apabetalone's synergy with SGLT2 inhibitors in reducing MACE in patients with (ACS) Acute Coronary Syndrome.
G1945V